Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease

Background: The correlation between 5′-Nucleotidase (5′-NT) and the clinical outcomes in coronary artery disease (CAD) patients following percutaneous coronary intervention (PCI) is not clear. This study aims to clarify this relationship. Methods: The PRACTICE study enrolled 15,250 patients between...

Full description

Bibliographic Details
Main Authors: Mikereyi Aimaitijiang, Ting-Ting Wu, Ying-Ying Zheng, Xian-Geng Hou, Haitao Yang, Yi Yang, Xiang Xie
Format: Article
Language:English
Published: IMR Press 2024-01-01
Series:Reviews in Cardiovascular Medicine
Subjects:
Online Access:https://www.imrpress.com/journal/RCM/25/1/10.31083/j.rcm2501017
_version_ 1797338521437995008
author Mikereyi Aimaitijiang
Ting-Ting Wu
Ying-Ying Zheng
Xian-Geng Hou
Haitao Yang
Yi Yang
Xiang Xie
author_facet Mikereyi Aimaitijiang
Ting-Ting Wu
Ying-Ying Zheng
Xian-Geng Hou
Haitao Yang
Yi Yang
Xiang Xie
author_sort Mikereyi Aimaitijiang
collection DOAJ
description Background: The correlation between 5′-Nucleotidase (5′-NT) and the clinical outcomes in coronary artery disease (CAD) patients following percutaneous coronary intervention (PCI) is not clear. This study aims to clarify this relationship. Methods: The PRACTICE study enrolled 15,250 patients between December 2016 and October 2021. After filtering out those without 5′-NT data, a total of 6555 patients were analyzed with a median follow-up of 24 months. Based on the receiver operating characteristic (ROC) curve analysis, a 5′-NT level of 5.57 U/L was selected as the optimal cutoff value. All research samples were divided into high-value (≥5.57 U/L, n = 2346) and low-value groups (<5.57 U/L, n = 4209). Key clinical outcomes included all-cause death (ACD), cardiovascular death (CD), major adverse cardiovascular events (MACE), and major adverse cardiovascular and cerebrovascular events (MACCE). After separating patients into high and low value groups, multivariate Cox regression analysis was used to correct for potential confounding variables. Finally, risk ratios and their 95% confidence intervals (CIs) were calculated. Results: During the follow-up period, 129 instances of ACD were recorded—49 cases (1.2%) in the low-value group and 80 cases (3.4%) in the high-value group. Similarly, 102 CDs occurred, including 42 low-value group cases (1.0%) and 60 high-value group cases (2.6%). A total of 363 MACE occurred, including 198 low-value group cases (4.7%) and 165 high-value group cases (7%). A total of 397 cases of MACCE occurred, including 227 low-value group cases (5.4%) and 170 high-value group cases (7.2%). As serum 5′-NT increased, the incidence of ACD, CD, MACE and MACCE increased. After multivariate Cox regression, high 5′-NT levels were linked with a 1.63-fold increase in ACD risk (hazard ratio [HR] = 2.630, 95% CI: [1.770–3.908], p < 0.001) when compared to low 5′-NT patients. Similarly, the risk of CD, MACE, and MACCE increased by 1.298-fold (HR = 2.298, 95% CI: [1.477–3.573], p < 0.001), 41% (HR = 1.410, 95% CI: [1.124–1.768], p = 0.003) and 30.5% (HR = 1.305, 95% CI: [1.049–1.623], p = 0.017), respectively. Conclusions: high serum 5′-NT levels were independently correlated with adverse clinical outcomes in CAD patients following PCI, affirming its potential as a prognostic indicator.
first_indexed 2024-03-08T09:32:27Z
format Article
id doaj.art-f21bdda8dd6d4fafa22c5786ebb1ec0a
institution Directory Open Access Journal
issn 1530-6550
language English
last_indexed 2024-03-08T09:32:27Z
publishDate 2024-01-01
publisher IMR Press
record_format Article
series Reviews in Cardiovascular Medicine
spelling doaj.art-f21bdda8dd6d4fafa22c5786ebb1ec0a2024-01-31T01:12:56ZengIMR PressReviews in Cardiovascular Medicine1530-65502024-01-012511710.31083/j.rcm2501017S1530-6550(23)01132-8Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery DiseaseMikereyi Aimaitijiang0Ting-Ting Wu1Ying-Ying Zheng2Xian-Geng Hou3Haitao Yang4Yi Yang5Xiang Xie6Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaDepartment of Cardiology, First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, ChinaBackground: The correlation between 5′-Nucleotidase (5′-NT) and the clinical outcomes in coronary artery disease (CAD) patients following percutaneous coronary intervention (PCI) is not clear. This study aims to clarify this relationship. Methods: The PRACTICE study enrolled 15,250 patients between December 2016 and October 2021. After filtering out those without 5′-NT data, a total of 6555 patients were analyzed with a median follow-up of 24 months. Based on the receiver operating characteristic (ROC) curve analysis, a 5′-NT level of 5.57 U/L was selected as the optimal cutoff value. All research samples were divided into high-value (≥5.57 U/L, n = 2346) and low-value groups (<5.57 U/L, n = 4209). Key clinical outcomes included all-cause death (ACD), cardiovascular death (CD), major adverse cardiovascular events (MACE), and major adverse cardiovascular and cerebrovascular events (MACCE). After separating patients into high and low value groups, multivariate Cox regression analysis was used to correct for potential confounding variables. Finally, risk ratios and their 95% confidence intervals (CIs) were calculated. Results: During the follow-up period, 129 instances of ACD were recorded—49 cases (1.2%) in the low-value group and 80 cases (3.4%) in the high-value group. Similarly, 102 CDs occurred, including 42 low-value group cases (1.0%) and 60 high-value group cases (2.6%). A total of 363 MACE occurred, including 198 low-value group cases (4.7%) and 165 high-value group cases (7%). A total of 397 cases of MACCE occurred, including 227 low-value group cases (5.4%) and 170 high-value group cases (7.2%). As serum 5′-NT increased, the incidence of ACD, CD, MACE and MACCE increased. After multivariate Cox regression, high 5′-NT levels were linked with a 1.63-fold increase in ACD risk (hazard ratio [HR] = 2.630, 95% CI: [1.770–3.908], p < 0.001) when compared to low 5′-NT patients. Similarly, the risk of CD, MACE, and MACCE increased by 1.298-fold (HR = 2.298, 95% CI: [1.477–3.573], p < 0.001), 41% (HR = 1.410, 95% CI: [1.124–1.768], p = 0.003) and 30.5% (HR = 1.305, 95% CI: [1.049–1.623], p = 0.017), respectively. Conclusions: high serum 5′-NT levels were independently correlated with adverse clinical outcomes in CAD patients following PCI, affirming its potential as a prognostic indicator.https://www.imrpress.com/journal/RCM/25/1/10.31083/j.rcm25010175′-nucleotidase (5′-nt)coronary artery disease (cad)cd73prognosis
spellingShingle Mikereyi Aimaitijiang
Ting-Ting Wu
Ying-Ying Zheng
Xian-Geng Hou
Haitao Yang
Yi Yang
Xiang Xie
Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease
Reviews in Cardiovascular Medicine
5′-nucleotidase (5′-nt)
coronary artery disease (cad)
cd73
prognosis
title Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease
title_full Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease
title_fullStr Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease
title_full_unstemmed Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease
title_short Serum 5′-Nucleotidase as a Novel Predictor of Adverse Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease
title_sort serum 5 nucleotidase as a novel predictor of adverse clinical outcomes after percutaneous coronary intervention in patients with coronary artery disease
topic 5′-nucleotidase (5′-nt)
coronary artery disease (cad)
cd73
prognosis
url https://www.imrpress.com/journal/RCM/25/1/10.31083/j.rcm2501017
work_keys_str_mv AT mikereyiaimaitijiang serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease
AT tingtingwu serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease
AT yingyingzheng serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease
AT xiangenghou serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease
AT haitaoyang serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease
AT yiyang serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease
AT xiangxie serum5nucleotidaseasanovelpredictorofadverseclinicaloutcomesafterpercutaneouscoronaryinterventioninpatientswithcoronaryarterydisease